Minority-Based CCOP at UMDNJ-NJ Medical School/University Hospital Cancer Center

描述（由申请人提供）：新泽西医学和牙科大学-新泽西医学院/大学医院癌症中心的少数民族社区临床肿瘤学项目成立于三年前。我们的计划服务于患者人群，主要来自纽瓦克的内城社区，周围的城镇和埃塞克斯县的城市社区。超过60%的患者是非洲裔美国人和拉丁美洲人，他们的收入不成比例地低，贫困率高，癌症死亡率高。大学医院肿瘤登记处每年记录约1000例新发癌症病例，其中头颈癌、肝癌和宫颈癌的发病率不成比例地高。我们还看到大量的乳腺癌、胃肠道肿瘤、前列腺肿瘤、肺癌和脑瘤病例。癌症中心的医生合作提供团队治疗方法。每个新患者都在7个疾病特异性肿瘤委员会或大圆桌会议中提出。癌症中心社区在与周围社区的联系方面有着卓越的记录，其项目包括筛查和教育，移动的乳腺癌和宫颈癌筛查项目以及埃塞克斯县联盟，所有这些都承诺招募少数民族患者参加我们的MBCCOP研究。我们已经从6个研究基地开展了50多项预防/控制和治疗试验，为大多数肿瘤类型以及我们的患者从癌症或其治疗中经历的许多症状和不良事件提供了方案。我们的癌症中心临床研究办公室及其工作人员在研究中积累和维护少数民族患者方面拥有丰富的经验。我们将使用来自社区的患者研究导航员来建立信任，我们将使用IRB批准的新型“同意助手”流程来获得非英语患者的知情同意，我们将结合外展专家的经验来教育社区中的患者有关临床试验。我们已经证明，越来越多的协议，并增加努力教育医生的可用临床试验增加转诊。我们概述了一个模型，该模型将确保每年有50多名少数民族患者参加癌症控制和治疗试验。

DESCRIPTION (provided by applicant): The Minority-Based Community Clinical Oncology Program at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School/University Hospital Cancer Center was established a three years ago. Our program serves a patient population which is primarily form the inner city neighborhoods of Newark, surrounding towns and urban communities of Essex County. The more than 60% of the patients are African American and Latino and have disproportionately low income, high poverty rates and high mortality from cancer. The University Hospital Tumor Registry records about 1000 new cancer cases a year, with disproportionately high incidence of head and neck, liver, and cervical cancer. We also see a high number of cases with breast, gastrointestinal, prostate, lung and brain tumors. The Cancer Center physicians work in collaboration to provide a team approach to therapy. Each new patient is presented at one of 7 disease specific tumor boards or Grand Rounds. The Cancer Center Community has an exceptional track record in outreach to the surrounding community with programs that include the screening and education, a mobile breast and cervical cancer screening program and the Essex County Coalition, all of which have pledged to recruit minority patients to our MBCCOP studies. We have opened more than 50 prevention/control and treatment trials from 6 research bases to have protocols available for most tumor types and for many of the symptoms and adverse events our patients experience from cancer or their treatment. Our Cancer Center Clinical Research Office and its staff have extensive experience with accruing and maintaining minority patients on studies. We will use patient study navigators form the community to develop trust, we will use a novel IRB-approved 'Consent Aide' process for obtaining informed consent from non-English speaking patients and we will incorporate the experience of an outreach specialist to educate patients in the community about clinical trials. We have demonstrated that increased numbers of protocols and increased efforts to educate physicians of available clinical trials increased referral. We outline a model that will ensure accrual of more than 50 minority patients a year each on cancer control and treatment trials.